|
|
Volumn 15, Issue 2, 2008, Pages 121-126
|
|
New insights into the pathogenesis and treatment of chronic myeloproliferative disorders
a
|
|
Author keywords
Essential thrombocythemia; JAK2 V617F; Janus kinase 2 inhibitors; Myeloproliferative disorders; Polycythemia vera; Primary myelofibrosis
|
|
Indexed keywords
12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE;
3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE;
5 AZA 2' DEOXYCYTIDINE;
ACETYLSALICYLIC ACID;
ANAGRELIDE;
ANTIBODY;
ANTIHISTAMINIC AGENT;
AZACITIDINE;
BEVACIZUMAB;
BORTEZOMIB;
CLADRIBINE;
CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE;
DASATINIB;
ERLOTINIB;
GC 1008;
HYDROXYUREA;
JANUS KINASE 2;
JANUS KINASE INHIBITOR;
LENALIDOMIDE;
LESTAURTINIB;
PEGINTERFERON ALPHA2A;
POMALIDOMIDE;
PREDNISONE;
PROTEIN FARNESYLTRANSFERASE INHIBITOR;
SEROTONIN UPTAKE INHIBITOR;
TG 101209;
THALIDOMIDE;
THALIDOMIDE DERIVATIVE;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VATALANIB;
ALLOGENEIC STEM CELL TRANSPLANTATION;
BONE MARROW;
CLINICAL TRIAL;
CYTOPENIA;
DNA METHYLATION;
DRUG DOSE ESCALATION;
DRUG DOSE REDUCTION;
ENZYME INHIBITION;
ERYTHROMELALGIA;
EXERCISE;
FATIGUE;
GENE MUTATION;
HIGH RISK POPULATION;
HUMAN;
LOW DRUG DOSE;
MICROENVIRONMENT;
MYELOID METAPLASIA;
MYELOPROLIFERATIVE DISORDER;
NONHUMAN;
PATHOGENESIS;
PHLEBOTOMY;
POLYCYTHEMIA VERA;
PREVALENCE;
PRIORITY JOURNAL;
PRURITUS;
REVIEW;
SPLENOMEGALY;
THROMBOCYTHEMIA;
TREATMENT PLANNING;
CLINICAL TRIALS AS TOPIC;
ENZYME INHIBITORS;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
JANUS KINASE 2;
MUTATION;
MYELOPROLIFERATIVE DISORDERS;
|
|
EID: 40049103602
PISSN: 10656251
EISSN: 15317048
Source Type: Journal
DOI: 10.1097/MOH.0b013e3282f3debd Document Type: Review |
|
Times cited : (10)
|
|
References (52)
|
